Oral News and Research

RSS

Merck's ROTATEQ vaccine receives Prix Galien USA 2010 Award for Best Biotechnology Product

ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent), Merck's vaccine for rotavirus gastroenteritis in infants and children, received the Prix Galien USA 2010 Award for Best Biotechnology Product, Merck announced today.

30 Sep 2010

SCT transplantation benefits in Hodgkin's lymphoma is unclear

It remains an unresolved question whether adult patients with Hodgkin's lymphoma, a certain type of lymph node cancer, benefit from allogeneic stem cell transplantation (SCT) with an unrelated donor. This is due to the fact that studies are lacking that compare this therapy with autologous transplantation or conventional chemotherapy without SCT.

30 Sep 2010

Unique genetic markers point to patient response to SCV-07 treatment

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that researchers have identified two unique gene clusters that differentiated subjects who responded to treatment in the Company’s phase 2a proof of concept study of SCV-07 for the prevention of severe oral mucositis (OM; WHO grades 3-4) in patients with advanced head and neck cancer.

29 Sep 2010

Crocker Ventures announces acquisition of TMJ Implants

Crocker Ventures today announced that it has acquired TMJ Implants of Golden, Colo., the leading manufacturer of implants for the treatment of temporomandibular joint (TMJ) disorder.

29 Sep 2010

Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer

Medivation, Inc. and Astellas Pharma Inc. today announced treatment of the first patient in a second Phase 3 clinical trial of the investigational drug MDV3100, which expands the Phase 3 development of the novel, triple-acting oral androgen receptor antagonist into an earlier-stage patient population. Known as PREVAIL, the trial will evaluate MDV3100 in men with advanced prostate cancer who have not yet received chemotherapy. Initiation of the PREVAIL trial triggers a milestone payment to Medivation under its collaboration agreement with Astellas.

29 Sep 2010

Rigel earns $25M milestone payment from Astrazeneca for clinical development of fostamatinib

Rigel Pharmaceuticals, Inc. today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor. The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) that was announced by AstraZeneca earlier today.

29 Sep 2010

AMIA calls out specific challenges to proposed modifications to HIPAA Privacy and Enforcement Rules

In comments sent to Secretary Kathleen Sebelius at the U.S. Department of Health and Human Services, AMIA (American Medical Informatics Association) called out 10 specific challenges to proposed modifications to HIPAA Privacy and Enforcement Rules. AMIA's comments, sent on behalf of its membership of 4,000 informatics professionals, detail key issues of concern related to the Notice of Proposed Rulemaking (NPRM) on HIPAA modifications, along with suggestions for models of change.

29 Sep 2010

Researchers identify biomarker to predict tivozanib drug resistance

Researchers believe there may be a way to predict, based on individual tumors, those patients that are more likely to respond to the investigational new drug tivozanib.

29 Sep 2010

Intrauterine devices for treatment of endometrial cancer

Intrauterine devices, originally developed as contraceptives, can also be used to treat and cure cancer of the endometrium according to new research published online in the cancer journal, Annals of Oncology today (Wednesday 29 September). The finding opens the way for young women with the disease, which affects the lining of the womb, to be treated without the need for a hysterectomy, thus preserving their fertility until they have had all the children they want.

29 Sep 2010

XenoPort to present XP21279 clinical trial data at World Parkinson Congress meeting

XenoPort, Inc. announced today that new data from its first clinical trial of XP21279, a Transported Prodrug of L-Dopa, in Parkinson's disease patients will be presented at the upcoming World Parkinson Congress meeting in Glasgow, Scotland.

29 Sep 2010

Generex Biotechnology receives new patent for buccal drug delivery system

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has been awarded a new patent in Canada.

29 Sep 2010

Plackers joins OHA campaign to promote oral health awareness

Plackers, a leading brand of consumer oral care products, has partnered with Oral Health America, the nation's leading independent organization dedicated to eliminating oral disease through access, education and advocacy, on the Fall for Smiles program to promote oral health awareness nationwide.

28 Sep 2010

Venous thromboembolism drugs to experience robust growth by 2019

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven primarily by the launch and widespread uptake of novel oral anticoagulants, the combined markets for drugs used in the treatment and prophylaxis of venous thromboembolism will experience robust growth, increasing from $2.9 billion in 2009 to more than $5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

28 Sep 2010

Mucosis collaborates with PATH to pursue use of Mimopath technology in diarrhea vaccines

Dutch biotechnology company Mucosis B.V. announced today that it has entered into a collaboration agreement with the global health nonprofit organization PATH to pursue the use of the company's Mimopath technology in oral vaccines to prevent and treat severe diarrhea.

28 Sep 2010

GSK supports AHA policy statement on smokeless tobacco products

GlaxoSmithKline (GSK) Consumer Healthcare, a leader in helping smokers quit and the marketer of nicotine replacement therapy (NRT) products, including Nicorette and NicoDerm CQ, supports the findings of the American Heart Association (AHA) policy statement regarding smokeless tobacco products.

28 Sep 2010

Japanese Patent Office issues patent for ZIOPHARM Oncology's darinaparsin

ZIOPHARM Oncology, Inc. today announced that the Japanese Patent Office has issued a patent, Patent No. 4,571,408, with claims covering pharmaceutical compositions, including oral formulations, of various organic arsenic compounds, including darinaparsin (Zinapar or ZIO-101), and the use of these compositions and the organic arsenic compounds for the treatment of cancer, including as part of a combination therapy.

28 Sep 2010

Bayer’s new oral contraceptive receives FDA approval

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved a new oral contraceptive, Beyaz (drospirenone / ethinyl estradiol / levomefolate calcium tablets and levomefolate calcium tablets).

28 Sep 2010

Onconova Therapeutics to present Ex-RAD radioprotectant data at RRS Annual Meeting

Onconova Therapeutics, Inc. is presenting new data in five posters and an oral presentation this week summarizing several studies with the company's radioprotectant Ex-RAD- at the 56th Annual Meeting of the Radiation Research Society (RRS), September 25-29 in Maui, Hawaii.

28 Sep 2010

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

Chelsea Therapeutics International, Ltd. has initiated enrollment in a multinational, 12-week, double-blind Phase II trial designed to compare the efficacy and tolerability of CH-4051 against methotrexate (MTX) in 250 patients with rheumatoid arthritis (RA) who are experiencing an inadequate response to MTX treatment.

27 Sep 2010

S*BIO initiates SB939 Phase 2 clinical trial for metastatic prostate cancer

S*BIO Pte Ltd today announced the initiation of a Phase 2 clinical trial of SB939, its novel orally-active HDAC inhibitor, in patients with recurrent or metastatic prostate cancer (HRPC).

27 Sep 2010

Oral News and Research

Merck's ROTATEQ vaccine receives Prix Galien USA 2010 Award for Best Biotechnology Product

SCT transplantation benefits in Hodgkin's lymphoma is unclear

Unique genetic markers point to patient response to SCV-07 treatment

Crocker Ventures announces acquisition of TMJ Implants

Medivation and Astellas commence MDV3100 second Phase 3 clinical trial in advanced prostate cancer

Rigel earns $25M milestone payment from Astrazeneca for clinical development of fostamatinib

AMIA calls out specific challenges to proposed modifications to HIPAA Privacy and Enforcement Rules

Researchers identify biomarker to predict tivozanib drug resistance

Intrauterine devices for treatment of endometrial cancer

XenoPort to present XP21279 clinical trial data at World Parkinson Congress meeting

Generex Biotechnology receives new patent for buccal drug delivery system

Plackers joins OHA campaign to promote oral health awareness

Venous thromboembolism drugs to experience robust growth by 2019

Mucosis collaborates with PATH to pursue use of Mimopath technology in diarrhea vaccines

GSK supports AHA policy statement on smokeless tobacco products

Japanese Patent Office issues patent for ZIOPHARM Oncology's darinaparsin

Bayer’s new oral contraceptive receives FDA approval

Onconova Therapeutics to present Ex-RAD radioprotectant data at RRS Annual Meeting

Chelsea Therapeutics initiates CH-4051 Phase II trial in rheumatoid arthritis patients

S*BIO initiates SB939 Phase 2 clinical trial for metastatic prostate cancer

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News